Lartruvo®

Active substance

olaratumab

Holder

S.A. Eli Lilly N.V.

Status

Closed

Indication

in combination with doxorubicin for the treatment Advanced soft tissue sarcoma not amenable to curative treatment with surgery or radiotherapy and not previously treated with doxorubicin

Public documents

Approbation

Information for the patient

Informed consent

Last update

31/01/2018

Last updated on 13/02/2024